title: Management of refractory OAB in the non-neurogenic patient.
abstract: Overactive bladder (OAB) is one of the most common bothersome urological diseases. It also has a negative economic impact. Pathophysiology entails changes in neurogenic and myogenic factors, as well as urinary biomarkers such as nerve growth factor (NGF) and prostaglandins (PGs). With symptoms from OAB-Dry to OAB-Wet, the urodynamic pattern of OAB bladder is often characterized by idiopathic detrusor overactivity with lower threshold of sensation, diminished compliance and capacity. Treatment ranges from a combination of behavioral modifications (BM)/ pelvic floor muscle training (PFMT) to combinations of antimuscarinics, Botox injection, nerve stimulation and augmentation cystoplasty. Herein, a contemporary review on the different aspects of management of refractory OAB in patients without neuropathic disorders is presented.
authors.affiliation: Voiding Dysfunction and Female Urology, Urology& Nephrology Center, Mansoura University, Mansoura, Egypt, bassem_wadie@mans.edu.eg.
authors.forename: Bassem S
authors.initials: BS
authors.lastname: Wadie
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004599:Electric Stimulation Therapy / Q000379:methods*; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D017773:Pelvic Floor; D026741:Physical Therapy Modalities; D001743:Urinary Bladder / Q000601:surgery*; D053201:Urinary Bladder, Overactive / Q000628:therapy*
chemical_list: D018727:Muscarinic Antagonists; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A